Stockreport

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions

Vertex Pharmaceuticals Incorporated  (VRTX) 
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
PDF – All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 –– Al [Read more]